Contrave XR Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Contrave XR Availability in 2026

As anti-obesity medication prescribing continues to accelerate, providers are increasingly fielding questions from patients about Contrave XR availability. This guide provides a clinical and logistical overview of where things stand in 2026 — including supply status, cost considerations, prescribing implications, and tools to help your patients access their medication.

Contrave XR (Naltrexone HCl 8 mg / Bupropion HCl 90 mg extended-release) remains the only FDA-approved oral combination medication for chronic weight management. It targets both the hypothalamic appetite center and the mesolimbic reward system, making it a unique option in the anti-obesity pharmacotherapy toolkit.

Current Supply Timeline

As of early 2026, Contrave XR is not listed on the FDA's Drug Shortage Database. Currax Pharmaceuticals, the sole manufacturer, has not reported supply disruptions. However, localized availability issues persist for several reasons:

• Demand spillover from GLP-1 shortages: Ongoing supply constraints for Semaglutide (Wegovy/Ozempic) and Tirzepatide (Zepbound/Mounjaro) have driven increased prescribing of oral alternatives, including Contrave XR and Qsymia.
• No generic availability: As a brand-only product with a single manufacturer, Contrave XR has less supply chain redundancy than multi-source generics.
• Pharmacy stocking variability: Many retail pharmacies do not routinely stock Contrave XR and require special orders, creating 1–2 day delays that patients may interpret as a shortage.
• Formulary shifts: When payers add or remove Contrave XR from preferred tiers, demand can shift abruptly in affected markets.

Prescribing Implications

When managing patients on Contrave XR in the current environment, consider the following:

Titration and Treatment Continuity

Contrave XR requires a 4-week dose titration:

• Week 1: 1 tablet (8/90 mg) in the morning
• Week 2: 1 tablet morning + 1 tablet evening
• Week 3: 2 tablets morning + 1 tablet evening
• Week 4+: 2 tablets morning + 2 tablets evening (maintenance: 32/360 mg daily)

If a patient experiences a gap in treatment due to availability issues, re-titration may be necessary depending on the duration of the interruption. There is no established protocol for resumption after a break, but clinical judgment suggests re-titrating from Week 1 if the gap exceeds 7–10 days to minimize nausea and other dose-dependent side effects.

Safety Reminders

Contrave XR carries a boxed warning for suicidal thoughts and behaviors related to the Bupropion component. Monitor patients — particularly those under 25 and those with a history of depression or other psychiatric conditions — at each visit. Additional safety considerations include:

• Seizure risk: Bupropion lowers the seizure threshold. Contrave XR is contraindicated in patients with seizure disorders, eating disorders (anorexia/bulimia), or those undergoing abrupt discontinuation of alcohol, benzodiazepines, or barbiturates.
• Opioid interactions: Naltrexone blocks opioid receptors. Contrave XR is contraindicated in patients on chronic opioid therapy or in acute opioid withdrawal. Patients should discontinue opioids for 7–10 days before starting Contrave XR. Advise patients about the risk of reduced pain control if opioids are needed emergently.
• Hepatotoxicity: Naltrexone can cause hepatocellular injury at high doses. Monitor liver function in patients with pre-existing hepatic impairment.
• Blood pressure: Contrave XR can increase blood pressure and heart rate. Monitor at baseline and periodically during treatment, especially in patients with hypertension.

For a comprehensive drug interaction reference, see our clinical resource on Contrave XR drug interactions.

The Availability Picture

Patient reports of difficulty finding Contrave XR generally fall into three categories:

1. Pharmacy doesn't stock it: Most common. The pharmacy can order it (1–2 business day turnaround), but the patient perceives this as unavailability.
2. Temporarily out at a high-volume pharmacy: Occurs when a pharmacy that regularly dispenses Contrave XR experiences a demand spike. Usually resolves within days.
3. Insurance-driven access barriers: Prior authorization denials, step therapy requirements, or non-formulary status can prevent patients from filling their prescription regardless of physical availability.

Providers can help by proactively addressing these scenarios — setting expectations about potential pharmacy delays and assisting with prior authorizations when needed.

Cost and Access Landscape

The cost of Contrave XR remains a significant barrier for many patients:

• Retail cash price: $500–$842/month (120 tablets at maintenance dose)
• CurAccess Program: $99/month with free home delivery through Currax's partner pharmacies — available regardless of insurance status
• GoodRx partnership: ~$199/month cash price at participating pharmacies
• Manufacturer copay card (Contrave Connex): Commercially insured patients may pay as little as $30/month
• Insurance with prior auth: Copays typically $30–$150/month

Medicare Part D generally does not cover anti-obesity medications. Some state Medicaid programs are beginning to cover Contrave XR, but coverage remains inconsistent.

For patients struggling with cost, the CurAccess program is often the most reliable path. Providers can prescribe directly to a CurAccess partner pharmacy, and the medication is shipped to the patient.

Tools and Resources for Your Practice

Several tools can help streamline Contrave XR access for your patients:

• Medfinder for Providers: A free tool that helps providers and staff identify pharmacies with real-time Contrave XR availability. Useful for directing patients to pharmacies that have stock or for verifying availability before sending a prescription.
• CurAccess enrollment: Available through contravehcp.com. Prescribers can enroll patients directly and prescribe to partner pharmacies for $99/month home delivery.
• Prior authorization support: Currax offers PA support resources through the Contrave Connex program. Contact information is available on the HCP portal.
• Electronic prescribing: Ensure your EHR allows e-prescribing to mail-order and specialty pharmacies, which can improve access for patients in areas with limited local stock.

Looking Ahead

Several trends will shape Contrave XR availability and prescribing in the coming months:

• GLP-1 supply stabilization: As manufacturing capacity for Semaglutide and Tirzepatide expands, some demand pressure on oral alternatives like Contrave XR may ease.
• Potential generic entry: While no generic Contrave XR is approved as of 2026, patent expirations and potential ANDA filings could change the landscape in the medium term, potentially improving both availability and affordability.
• Expanding insurance coverage: Federal and state policy discussions about covering anti-obesity medications under Medicare and Medicaid continue to gain momentum, which could significantly expand patient access.
• New oral options in the pipeline: Oral GLP-1 formulations and other novel mechanisms are in late-stage clinical development, which may provide additional oral alternatives to Contrave XR in the future.

Final Thoughts

Contrave XR remains an important tool in the anti-obesity pharmacotherapy arsenal — particularly for patients who prefer oral therapy, cannot tolerate GLP-1 agonists, or face insurance barriers to injectable medications. While not in official shortage, real-world access challenges persist.

Proactive prescribing practices — including use of the CurAccess program, familiarity with patient assistance options, and leveraging tools like Medfinder for Providers — can help ensure your patients maintain treatment continuity.

For additional clinical resources, see our provider guides on helping patients find Contrave XR in stock and helping patients save money on Contrave XR.